Drug Trial Radar · NCT01769768
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients
Last checked: Nov 19, 2026Latest source record: Dec 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
114
Actual
Start
Apr 2013
Primary completion
Aug 2016
Study completion Aug 2016
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 17, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a multi center, open-label study to evaluate the drug-drug interaction of LDE225 on the PK of bupropion and warfarin patients with advanced solid tumors. Subjects will receive 800mg daily of LDE225 and two separate doses of either bupropion or warfarin.
Conditions
- Advanced Solid Tumor
Interventions
LDE225Drug
LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.
WafarinDrug
15 mg single dose of warfarin (oral tablet) will be given to patients.
BupropionDrug
75 mg single dose of bupropion(oral tablet, from an immediate release formulation) will be given to patients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK) parameter AUClast for S- and R-warfarinTime frame: 7 days
- PK parameter AUClast for bupropionTime frame: 7 days
- PK parameter AUCinf for bupropionTime frame: 7 days
- PK parameter AUCinf for S- and R-warfarinTime frame: 7 days
- PK parameter Cmax for S- and R-warfarinTime frame: 7 days
- PK parameters Cmax for bupropionTime frame: 7 days
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
City of Hope National Medical Center Oncology
Duarte, California
University of Kansas Medical Center CBYM338B2203
Kansas City, Kansas
Massachusetts General Hospital Dana-Farber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock Med Ctr
Lebanon, New Hampshire
Hackensack University Medical Center Dept.of HackensackUniv.MedCtr.
Hackensack, New Jersey
University of Pennsylvania--Abramson Cancer Center Abramson Cancer Center
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
University of Pittsburgh Cancer Institute UPMC Cancer Pavilion
Pittsburgh, Pennsylvania
Medical University of South Carolina Dept.of Neurosciences/MS Ctr.
Charleston, South Carolina
Cancer Centers of the Carolinas SC
Greenville, South Carolina
Utah Health Science Center at San Antonio
San Antonio, Texas
University of Utah / Huntsman Cancer Institute
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.